GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Aurobindo Pharma Ltd

Aurobindo Pharma: Board Approves Merger of Two Step-Down Subsidiaries

M&A ● No Immediate Change LOW RISK
📅 Filed on BSE: 05 Aug 2026, 08:09 PM IST  ·  BSE ID: f8cef38f-2bc8-4f04-84ff-ac7cfb323238
View Original BSE Filing (PDF)
💡
In Simple Terms
Aurobindo Pharma is combining three of its fully-owned drug manufacturing companies to streamline operations.
🤖 AI Summary
  • Aurobindo Pharma's Board approved the merger of Eugia Steriles and Eugia SEZ into Eugia Pharma Specialities.
  • Eugia Pharma, Eugia Steriles, and Eugia SEZ are wholly owned subsidiaries manufacturing injectable pharmaceuticals.
  • Eugia Pharma reported a turnover of INR 27,259.04 million for FY 2026.
  • Eugia Steriles and Eugia SEZ had turnovers of INR 62.7 million and INR 4,874.2 million for FY 2026 respectively.
  • The merger aims to simplify group structure, reduce overheads, and improve treasury management; no cash consideration.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Eugia Pharma Turnover FY 2026
27,259.04 INR million
Eugia Steriles Turnover FY 2026
62.7 INR million
Eugia SEZ Turnover FY 2026
4,874.2 INR million
🏢 How This Affects the Company
📈
Business Impact
The merger consolidates three entities engaged in manufacturing injectable pharmaceutical products, simplifying the overall group structure. This aims to integrate operations of companies carrying on substantially similar businesses into a single legal entity.
💰
Financial Impact
The amalgamation is intended to lead to the elimination of corporate and administrative functions, resulting in cost reduction and better treasury management. No cash consideration is involved, as it is a merger between wholly owned subsidiaries.
⚙️
Operational Impact
Consolidating three subsidiaries into one entity is designed to enhance synergy benefits and streamline corporate and administrative functions. This should lead to more efficient management of injectable pharmaceutical product manufacturing.
⚠️
Risk Impact
The simplification of the group structure through this merger can decrease complexities in regulatory compliance and internal management, potentially reducing administrative and operational risks associated with multiple legal entities.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders.
👤
Who Is Affected
Shareholders of Aurobindo Pharma Ltd are indirectly affected as this is an internal restructuring of its wholly owned subsidiaries. The shareholding pattern of the listed entity remains unchanged.
🔍
Management Signal
Management intends to simplify the corporate structure, reduce operational overlaps, and enhance cost efficiencies within its injectable pharmaceutical manufacturing segment.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
NCLT Hyderabad approval of the Scheme of Amalgamation for the merger.
Updates on the effective date of the merger and its operational integration.
Future financial disclosures reflecting the consolidated operational performance of Eugia Pharma.
LOW RISK This is an internal restructuring among wholly owned subsidiaries, with no external cash consideration involved.
💡 Investor Takeaway
Aurobindo Pharma's Board approved a proposal to merge Eugia Steriles (FY26 turnover INR 62.7 million) and Eugia SEZ (FY26 turnover INR 4,874.2 million) into Eugia Pharma (FY26 turnover INR 27,259.04 million). This internal restructuring aims to simplify the group structure and optimize operations.
⚖️ Strengths & Concerns

✅ Positives

  • Streamlines group structure by consolidating three wholly owned subsidiaries with substantially similar businesses into one legal entity.
  • Expected to eliminate corporate and administrative functions, reduce overheads, and improve treasury management, leading to synergy benefits.
📅 Company Track Record
This merger proposal follows a series of recent strategic activities by Aurobindo Pharma, including the acquisition of majority ownership in A1 Biochem Labs (India) in July 2026 for USD 17 million and the completion of Lannett Company, Inc. acquisition in June 2026.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
Which Aurobindo Pharma subsidiaries are involved in the proposed merger?
The proposed merger involves Eugia Steriles Private Limited and Eugia SEZ Private Limited merging with Eugia Pharma Specialities Limited, all wholly owned subsidiaries of Aurobindo Pharma.
What was the turnover of Eugia Pharma Specialities Limited for FY 2026?
Eugia Pharma Specialities Limited reported a turnover of 27,259.04 INR million for the financial year ended March 31st 2026.
What is the rationale behind Aurobindo Pharma's proposed merger of subsidiaries?
The proposed amalgamation aims to simplify the existing group structure by consolidating three companies engaged in similar businesses, leading to cost reduction, better treasury management, and synergy benefits.
Will there be any cash consideration for this merger between Aurobindo Pharma's subsidiaries?
No consideration is involved, as the proposed merger is an internal transaction between wholly owned subsidiaries and their holding company.
What were the turnovers for Eugia Steriles Private Limited and Eugia SEZ Private Limited for FY 2026?
For FY 2026, Eugia Steriles Private Limited had a turnover of 62.7 INR million, and Eugia SEZ Private Limited had a turnover of 4,874.2 INR million.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.